SCHEMBL16139727

SCHEMBL16139727

N#Cc1ccc(Nc2ccccc2)c2nonc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MYC P01106 6/20 0.54
MEN1 O00255 5/20 0.54
KMT2A Q03164 5/20 0.54
IDO1 P14902 4/20 0.54
HTT P42858 3/20 0.46
KDM4E B2RXH2 2/20 0.46
GAA P10253 2/20 0.46
MAPT P10636 2/20 0.46
LMNA P02545 1/20 0.46
HPGD P15428 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
POLB P06746 1/20 0.43
BCL6 P41182 1/20 0.43
BCOR Q6W2J9 1/20 0.43
MAX P61244 3/20 0.43
ALDH1A1 P00352 1/20 0.42
AURKA O14965 1/20 0.39
KDR P35968 1/20 0.38
TSHR P16473 1/20 0.38
RECQL P46063 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16141953 0.83 MYC (0.60) MYCMEN1KMT2AIDO1HTT
SCHEMBL7464263 0.77 MBOAT4 (0.37) TSHR
SCHEMBL16139719 0.73 MYC (0.55) MYCMEN1KMT2AIDO1POLB
SCHEMBL16139720 0.72 MYC (0.57) MYCMEN1KMT2AIDO1KDM4E
SCHEMBL20441084 0.71 MAPT (0.42) MEN1KMT2AHTTKDM4EGAA
SCHEMBL16139728 0.71 KMT2A (0.56) MYCMEN1KMT2AIDO1MAPT
SCHEMBL16004866 0.70 KMT2A (0.68) MYCMEN1KMT2AIDO1KDM4E
SCHEMBL20881623 0.70 KDM4E (0.76) MEN1KMT2AHTTKDM4EGAA
SCHEMBL4188631 0.70 AURKA (0.59) MEN1KMT2AHTTKDM4EGAA
SCHEMBL3712058 0.70 MEN1 (1.00) MYCMEN1KMT2AIDO1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242944-B2 Potent analogues of the C-Myc inhibitor 10074-G5 with improved cell permeability UNIVERSITY OF MARYLAND, BALTIMORE (US) 2016-01-26 US disclosed
US-20140296307-A1 POTENT ANALOGUES OF THE C-MYC INHIBITOR 10074-G5 WITH IMPROVED CELL PERMEABILITY UNIVERSITY OF MARYLAND, BALTIMORE (US) 2014-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296307-A1 POTENT ANALOGUES OF THE C-MYC INHIBITOR 10074-G5 WITH IMPROVED CELL PERMEABILITY MYC, MYCBP, MKI67 MYC 1/4885MEN1 204/4885KMT2A 1587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.